Evogene Ltd. (NASDAQ: EVGN) is -8.72% lower on its value in year-to-date trading and has touched a low of $0.90 and a high of $10.24 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EVGN stock was last observed hovering at around $4.45 in the last trading session, with the day’s loss setting it -0.16% off its average median price target of $15.00 for the next 12 months. It is also 71.4% off the consensus price target high of $15.00 offered by 1 analysts, but current levels are 71.4% higher than the price target low of $15.00 for the same period.
Currently trading at $4.29, the stock is -17.72% and -33.61% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing -3.60% at the moment leaves the stock 19.48% off its SMA200. EVGN registered 304.72% gain for a year compared to 6-month gain of 10.28%. The firm has a 50-day simple moving average (SMA 50) of $6.4444 and a 200-day simple moving average (SMA200) of $4.6405.
The stock witnessed a -26.92% loss in the last 1 month and extending the period to 3 months gives it a -2.72%, and is -21.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.89% over the week and 12.48% over the month.
Evogene Ltd. (EVGN) has around 143 employees, a market worth around $173.26M and $0.81M in sales. Distance from 52-week low is 376.67% and -58.10% from its 52-week high.
Evogene Ltd. (EVGN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Evogene Ltd. (EVGN) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Evogene Ltd. is expected to release its quarterly report on 06/01/2021 and quarterly earnings per share for the current quarter are estimated at -$0.18 with sales reaching $300k over the same period.The EPS is expected to grow by 16.90% this year, but quarterly earnings will post -3.80% year-over-year.
Evogene Ltd. (EVGN) Top Institutional Holders
21 institutions hold shares in Evogene Ltd. (EVGN), with 5.73M shares held by insiders accounting for 18.12% while institutional investors hold 29.21% of the company’s shares. The shares outstanding are 40.39M, and float is at 29.09M with Short Float at 2.94%. Institutions hold 23.92% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 4.59 million shares valued at $21.59 million. The investor’s holdings represent 12.59% of the EVGN Shares outstanding. As of Dec 30, 2020, the second largest holder is Waddell & Reed Financial Inc. with 2.76 million shares valued at $12.96 million to account for 7.56% of the shares outstanding. The other top investors are SilverArc Capital Management, LLC which holds 0.6 million shares representing 1.64% and valued at over $2.82 million, while Senvest Management LLC holds 1.30% of the shares totaling 0.47 million with a market value of $2.23 million.
Evogene Ltd. (EVGN): Who are the competitors?
The company’s main competitors (and peers) include 22nd Century Group Inc. (XXII) that is trading 285.60% up over the past 12 months and Compugen Ltd. (CGEN) that is 9.75% higher over the same period. Short interest in the company’s stock has fallen -61.58% from the last report on Feb 11, 2021 to stand at a total of 1.38 million short shares sold with a short interest ratio of 0.51.